Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: monoclonal antibodies - PharmAbcine

Drug Profile

Research programme: monoclonal antibodies - PharmAbcine

Alternative Names: anti-KDR mAb; DIG KT; PIG KM; PMC-001; PMC-005B; PMC-201; PMC-309; PMC-309a-z; PMC-401; SSS-25; TRPH 011; VEGFR-2/TIE-2 - PharmAbcine/Triphase Accelerator Corporation

Latest Information Update: 03 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PharmAbcine
  • Developer PharmAbcine; Triphase Accelerator Corporation
  • Class Anti-inflammatories; Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Angiopoietin-2 inhibitors; Proto oncogene protein c met inhibitors; TIE 2 receptor antagonists; Vascular endothelial growth factor receptor-2 antagonists; VISTA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer; Glioblastoma; Pancreatic cancer
  • No development reported Inflammation

Most Recent Events

  • 01 Apr 2018 Preclinical development is ongoing South Korea
  • 01 Apr 2018 PMC 005B is available for licensing as of 01 Apr 2018.
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in South Korea (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top